In the APTITUDE study, a multicenter phase 2 single-arm trial, 21 pediatric patients with JIA-associated uveitis previously refractory to methotrexate, and TNF-alpha inhibitors were treated with subcutaneous tocilizumab over six months [13]. This evidence concerns the gene TNF and uveitis.